Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
So, why did the SEC commit the resources to implement RegSHO in 2005 if it does not help protect investors and provide useful information ?
Portraying RegSHO as useless seem like a "silly statement" to me.
Regulation SHO
Compliance with Regulation SHO began on January 3, 2005. Regulation SHO was adopted to update short sale regulation in light of numerous market developments since short sale regulation was first adopted in 1938 and to address concerns regarding persistent failures to deliver and potentially abusive “naked” short selling.
Due to continued concerns about failures to deliver, and to promote market stability and preserve investor confidence, the Commission has amended Regulation SHO several times since 2005 to eliminate certain exceptions, strengthen certain requirements and reintroduce the price test restriction.
Do you believe that all Broker/Dealer Shorting is Covered in 3 days?
Do you believe that all Broker/Dealer Trading is listed on the Time/Sales data that one sees from Schwab, TD Ameritrade, Fidelity, ect.?
Yep
Date ... Symbol .. Short vol .. Total vol
20230427 | BIEL | 4077502 | 5108002
https://cdn.finra.org/equity/regsho/daily/FORFshvol20230427.txt
I am saying everything is relative and cherry picking can be hazardous
Someone got excited about 3, .0003 Opening Trades without mentioning that those 3 Trades totaled 13,000 shares or $3.90 .
2 minutes after the Opening a 2.2 million share, over $900, Trade occurred at a .0004 price.
This Trade shut down the 3 Bid and raised the Bid Price to 4 with a 7.8 million Size and the Ask to 5.
Forgot to mention the "Massive Volume" of that 3 Opening
3 Trades:
1,000 shares, or 30 cents
2,000 shares, or 60 cents
10,000 shares or 3 dollars
2 minutes 40 seconds after that historic 3 opening a 2.2 million share Buy @ 4 .
23 Million shares Shorted Today per FINRA's Daily Short Volume Report
Date .... Symbol .. Short vol .. Total vol
20230426 | BIEL | 23177900 | 54787208
https://cdn.finra.org/equity/regsho/daily/FORFshvol20230426.txt
If BIEL is "Doomed" who is Buying all of those 4s?
We have an endless supply 4s, the bucket miraculously refilling over and over again.
33 million in AH Trades at 3.9 .
There is accumulation by someone at 4.
Important to mention that no Pain Remedy 'works for everyone'
When It Comes To Pain Relief, One Size Doesn't Fit All
September 26, 2011 NPR
"In a massive review of current studies and research published earlier this month, scientists at Oxford University in England examined 350 different studies involving about 45,000 patients. They looked at doses of single painkillers as well as combinations of drugs, totaling 38 different pain medications — everything from acetaminophen, aspirin and ibuprofen to more powerful opiate derivatives."
"Biochemist Andrew Moore headed the study, which aimed to explore whether one medication worked "best" for most people. Their conclusion: No. Certain pain medications which worked to relieve pain for certain individuals were barely noticeable for others."
https://www.npr.org/sections/health-shots/2011/09/26/140705557/when-it-comes-to-pain-relief-one-size-doesnt-fit-all
'Number Needed to Treat', NNT, is a standard used to evaluate the effectiveness of Pain Relievers. It measures how many patients must be treated for one to achieve a 50% reduction in their pain. The closer to a value of 1 the better the medication.
Common Pain Meds and NNT score:
Medication ............ Type of Medication ..................... Study Size ....... NNT
Diclofenac ..............100 mg Prescription NSAID ..................545 ..............1.8
Celecoxib................400 mg Prescription NSAID ................ 298 .............. 2.1
Ibuprofen ............... 400 mg Prescription NSAID .............. 5456 ..............2.5
Naproxen ............... 400 mg Prescription NSAID ................ 197 ...............2.7
Ibuprofen ............... 200 mg OTC NSAID ......................... 3248 .............. 2.7
Oxycodone 10 mg +
Acetaminophen ......1000 mg Prescription opioid ................. 83 ............... 2.7
Morphine ....................10 mg Injectable opioid ................... 948 ............... 2.9
Oxycodone 5 mg +
Acetaminophen ........ 325 mg Prescription opioid ............... 149 ............... 5.5
Tramadol ....................50 mg Prescription opioid ................ 770 ...............8.3
https://www.nsc.org/getmedia/8ecdc0e5-ae58-43e8-b98b-46c205e1c2b2/evidence-efficacy-pain-medications.pdf
BIEL has seen the .0003s and even the .0002s, Always Bounces Back
Every time BIEL slips into the triple zeros we hear proclamations of 'BIEL is Finished'. These proclamations have always been wrong.
BIEL, like many OTC companies, is a news driven stock. BIEL dips when there is no significant news and shoots up when an important PR comes out.
BIEL had been trading in the triple zeros from mid February through mid October of 2020. In November 2020 BIEL announced the DonJoy Marketing Deal and the CE Mark Approval. December 2020 saw the announcement of the KT Tape OEM Deal. BIEL rose to a high of .008 on 2/17/2021.
At the end 2016 investors were weary of waiting for an FDA Clearance. In November & December 2016 BIEL dipped to .0002 intraday on multiple days. On 1/31/2017 BIEL dipped into the 2s again. On 2/1/2017 BIEL Closed at .0003. On 2/6/2016 BIEL shot up to .0019 as news of the FDA Clearance for Foot and Knee Pain emerged. BIEL reached .003 on 2/16/2017 on this news.
In January and early February of 2014 investors were weary of waiting for progress on an FDA Reclassification. BIEL had dipped into the .0003s and .0004s on multiple days. BIEL had been lobbying the FDA for changing its Medical Device Classification from a Type 3 Device to a Type 2 which would make FDA Clearances simpler. On 2/21/2014 news broke that the FDA was recommending the Reclassification. BIEL shot up to .003 and hit .0084 on 2/24/2014.
Someone was concerned that BIEL had spent money on Allay packaging
<<<<<<<<< They spent money on packaging for Allay, but it's on the back burner? >>>>>>>>>
I pointed out that Allay had CE Mark regulatory approval in 2010 and was selling in Europe.
Convertible note holders must convert before they have access to shares
Market Makers on the other hand can sell shares they do not own any time they want
<<<<<<<<<< I forgot she has a 21B ATM >>>>>>>>>>>>>
Financial statements show the last IBEX conversion was 3/22/2019, over 4 years ago.
Hmmmm, 12 million shares @ 5 in First Hour of Trading
Go BIEL !!!
Per a 2010 Allay website it was for sale in 40 countries
Inside the box, you will find:
1 12cm Allay Loop Device Inside a Cloth Wrap
1 Pouch (Allay device inside)
9 Additional Cloth Wraps!
Allay is currently being sold in over 40 countries worldwide.
Patient Testimonials
"Once I started using Allay, I forgot that I was on my period because there was no pain!
©2010 BioElectronics Corporation | 4539 Metropolitan Ct. Frederick, MD 21704 | 1-866-757-2284
http://web.archive.org/web/20100719201321/https://www.bielcorp.com/products/allay/
http://web.archive.org/web/20130617044500/http://www.bielcorp.com/distributors/market-clearances
MMs can Sell at the Bid Price and that transaction is recorded as a Sell
MMs can also Sell at the Ask Price and that transaction is recorded as a Buy.
Both scenarios could involve selling shares that the MM does not own and has not borrowed, Naked Shorting.
In the 1/26/2021 example with 309 million shares shorted:
* The SP did not rise 60% from trading on the 26th
* The SP Closed at .002373 on the 25th
* The SP Opened at .003 on the 26th
* .000627 of the SP rise happened overnight, not from trading on the 26th
* The SP rise from trading on the 26th was .003 Open to .00395 Close or 31.6%
* Large volume days for BIEL are not linear, there are many peaks and valleys
* On the 26th the High was .004 and the Low was .00245
* This wide spread in SP is a cash cow for MMs, their computers calculating the optimum point to sell at the peaks and buy in the valleys if a bounce is probable
* I used your .0001 calculation from yesterday to keep things simple but with the wide swing in price MMs most likely raked in $75k+ from trading on 1/26/2021.
************************************************************************************
<<<<<< How many of those Daily short volume shares end up on a failed to deliver report >>>>>>
As stated yesterday and NUMEROUS TIMES BEFORE, This is not about Long Term Shorting that shows up on the Bi-Monthly Short Report. It is about 'Short Term' Shorting to manipulate the SP for a few days to 13 days and then covering the short before the shorting is recorded on the Bi-Monthly Short Report.
**************************************************************************************
<<<<<<<<< there is no indication that that is happening here >>>>>>>>>>>
Shorting OTC stocks to manipulate the SP and increase profits is a no brainer for Market Makers as the SEC generally ignores this issue. To get an idea of the corporate mind set regarding violating SEC Rules look at our friends at Citadel who had $7.5 billion in revenue last year. The SEC has taken over 58 actions against Citadel over the last 16 years for violating its regulations.
Nobody goes to jail and it ends up being a 'cost of doing business' fine for Citadel:
"The sole purpose of the SEC (Securities and Exchange commission) is to protect investors. The SEC is a U.S government agency that is responsible for maintaining a fair, honest, and trustworthy market. As investors we put our trust into them when it comes to making sure they enforce the law against market manipulation. While it’s great to see fines imposed, it seems clear that these fines mean little to no thing to firms like Citadel, as they have no fear in continuing breach rules and regulations. How many times will firms be able to break the law and disobey set rules before they start facing fines that actually create financial hardship for them or banned completely?"
********************************************************
"FINRA (Financial Industry Regulatory Authority) is an independent company that works under the SEC to regulate brokerages. In July of 2020, FINRA announced that it had fined Citadel Securities $700,000 for yet again, breaching rules and regulations. Citadel Securities breached FINRA rule 5320 and FINRA rule 6460, which is “Prohibition Against Trading Ahead of Customer Orders” and “Display of Customer Order Limits”. Without contest, Citadel Securities took the hit with the fine and agreed to pay."
"Following the $700,000 fine in 2020, FINRA again fined Citadel, this time $275,000 for additional violations of reporting requirements in 2021."
*************************************************************
"One of the largest financial hits that Citadel Securities took was in 2017, when the brokerage agreed to pay $22.6 million in settlement charges for misleading clients about the way it priced trades. According to a 2017 press release from the SEC, Citadel used two different algorithms that failed to internalize retail orders at the best price observed in the market. The two strategies were known as “Fastfill” and “SmartProvide”, which have since been discontinued."
"At the time Stephanie Avakian, Acting Director of the SEC Enforcement Division said, “Citadel Securities made misleading statements suggesting that it would provide or try to get the best prices it saw for retail orders routed by other broker-dealers. Internalizers can’t suggest they are doing one thing yet do another when it comes to pricing trades.” "
***********************************************************************
"December of 2018 Citadel Securities was among one of three broker-dealers that agreed to collectively pay a penalty settlement of over $6 million dollars for providing the SEC with incomplete and inaccurate securities trading information. According to the SEC, Citadel Securities LLC, Natixis Securities Americas LLC and MUFG Securities Americas Inc, provided incomplete and inaccurate “blue sheet data” to the SEC. The “blue sheet data” is used by the SEC so that they can enforce and carry out regulatory obligations such as investigating fraudulent activity and insider trading."
"These three broker-dealers repeatedly submitted blue sheets with missing data and information — which naturally interferes with the SEC’s ability to properly regulate. Citadel Securities submitted inaccurate data for nearly 80 million trades. Ultimately Citadel agreed to be censured and paid $3.5 million in penalties."
Lets take a look at "not much profit"
<<<<< 5 million shares trade with a spread of 0.0001? That's not much profit to spread around >>>>>
5 million shares x .0001 = $500 and that was a computer executed trade no human involvement required.
On 1/26/2021 with a total volume of 426 million shares MMs shorted 309 million shares.
And 309 million x.0001 = $30,900 .
MMs are supposed to keep an inventory of shares of all the companies they cover because all transactions flow through the MM, you and I buy from and sell to an MM. If the MM that shorted the 5 million shares yesterday used his BIEL inventory to sell those 5 million shares it would not be on the Daily Short Report. But why tie up money in share inventory when you can Naked Short with impunity
The large Market Makers handle thousands of thousands of companies. Citidel alone is the Market Maker for 6,300 OTC companies, do the math.
YUUUUGE Fake News at 7:59 pm
<<<<<<<<<< YUUUUUGE SELLS AT EOD. >>>>>>>>>>>>
There was only 1 trade after 12 noon yesterday, a 390k share ($156) Sell @ 2:04 .
#NoShame
You are confusing the Daily Short Sale Volume Files with the Bi-Monthly Short Interest Report, Two Separate Reporting Requirements
The MMs shorted 5 million shares on 4/20/2023 that is shown on the Daily Short Sale Volume Files, Reg SHO Rules. Nothing changes that fact. They could cover that shorting tomorrow or in 3 days or in 10 days and it does not change the fact that on 4/20/2023 MMs sold 5 million shares that they did not own and had not borrowed, Naked Shorting.
If the MMs have not covered their shorting after 13 days it goes on the Bi-Monthly Short Report
“The Daily Short Sale Volume Files provide aggregated volume by security for all short sale trades executed and reported to a TRF, the ADF, or the ORF during normal market hours for public dissemination purposes (i.e., media-reported trades). The short interest data reflects aggregate short positions held by market participants at a specific moment in time on two discrete days each month, while the Daily Short Sale Volume reflects the aggregate volume of trades executed and reported as short sales on each trade date.”
**********************************************************************************************
Bi-Monthly Short Reporting
"Pursuant to FINRA Rule 4560, member firms are required to report total short positions in all customer and proprietary firm accounts in all equity securities to FINRA on a bi-monthly basis. These filings are made online using the Short Interest reporting system accessible via FINRA Gateway at gateway.finra.org."
"The Reporting Period: Firms must report their mid-month short positions as of the close of business on the settlement date of the 15th of each month or, where the 15th is a non settlement date, on the preceding settlement date. Firms must report their end-of-month short positions as of the close of business on the last business day of the month on which transactions settle."
**************************************************************************************************
A pretty simple system, one tracks 'Short Term' Shorting the other tracks 'Long Term' Shorting. I have never said there was 'Long Term' Shorting in BIEL.
MMs are very happy to manipulate a SP on a daily basis by selling shares they do not own and covering the Naked Shorting before it has to be recorded as a 'Long Term' Short. If they are questioned about the shorting of a particular stock they claim the MM 'Making a Market' Exemption. They were just making sure that the stock had Liquidity and investors could always Buy & Sell that stock, to do that they had to sell shares that they did not own and had not borrowed.
Computers control all of the trading and the MMs program their computers to make them the highest profits possible within the rules of the game. The 'Making a Market' Exemption and up to nearly 2 week grace period to cover shorting give them a lot of opportunities to maximize profits.
Forgot one significant stat
Look at that, 20.6 million shares were Naked Shorts this week.
Date ... Symbol .. Short vol .. Total vol
20230420 | BIEL | 5000000 | 12474000
20230419 | BIEL | 8722647 | 9206869
20230418 | BIEL | 3000000 | 5410932
20230417 | BIEL | 3925000 | 6759357
https://cdn.finra.org/equity/regsho/daily/FORFshvol20230420.txt
https://cdn.finra.org/equity/regsho/daily/FORFshvol20230419.txt
https://cdn.finra.org/equity/regsho/daily/FORFshvol20230418.txt
https://cdn.finra.org/equity/regsho/daily/FORFshvol20230417.txt
“The Daily Short Sale Volume Files provide aggregated volume by security for all short sale trades executed and reported to a TRF, the ADF, or the ORF during normal market hours for public dissemination purposes (i.e., media-reported trades). The short interest data reflects aggregate short positions held by market participants at a specific moment in time on two discrete days each month, while the Daily Short Sale Volume reflects the aggregate volume of trades executed and reported as short sales on each trade date.”
Ridiculous Opinion, a Loan is a binding contract
<<<<<<<<< they were rolled over because there is NO MONEY or STOCK >>>>>>>>>
A lender can demand payment at maturity. If BIEL couldn't come up with the cash they would need to increase the AS as needed to repay the loan.
The lenders that are 'Rolling Over' loans want to see BIEL succeed and probably have access to more BIEL information than the average investor..
Not guessing at anything
It is all stated in the 'Time/Sales" data and the FINRA Reg SHO Daily Report.
Date .... Symbol ..Short vol ..Total vol
20230419 | BIEL | 8722647 | 9206869
Buys = 5 million shares
Sells = 3.1 million shares
Neutral = 1 million shares @ .00045
Naked Shorting = 8.7 million shares
Nice try, all of those lenders are 'Friendly Lenders', having previously Rolled Over numerous loans when they came due.
Nice touch throwing in Fantasy Sales-Track, the company that only exists in someone's mind, at the end.
Welcome to Planet Earth
Here Red means Stop & Green means Go.
Selling 8.7 million shares, that do not exist, into a trading day with 9.2 million shares total volume is not "holding this price UP"
If MMs wanted to support a SP they would be Buying at the Ask instead of selling millions of phantom shares.
Another 5 million share Buy at the open
Buys = 5 million
Sells = 11,500
MMs were the Only Ones Selling Today
Date .... Symbol ..Short vol ..Total vol
20230419 | BIEL | 8722647 | 9206869
Buys = 5 million shares
Sells = 3.1 million shares
Neutral = 1 million shares @ .00045
Naked Shorting = 8.7 million shares
Ouch, Last Sell was at 9:50, 3 hours with No Sells
BIEL now at 5, Buys now outnumber Sells by 2 million shares.
Open the wallet and pay .0005 if you want shares.
This sound familiar,1/2023,
"Come on .0004!!
Then back to .0006!!
I want another Tesla.
LOWER LOWS"
I am looking "at that volume" right now, 1.3 million shares after an hour of trading
$542 in two trades.
Those who want shares should pay Market price rather than trying to scare investors into selling with their BS.
BIEL's stock has been their currency for over 15 years
On 12/31/2022 with the SP bouncing between .0005 and .0006 and factoring in the 50% conversion discount it would have taken 21.5 billion shares to satisfy the IBEX debt.
On 7/30/21 with an average SP at .003 it would have taken 4.3 billion shares.
On 2/26/21 with an average SP at .006 it would have taken 2.15 billion shares.
The average SP back in September 2009 of .08 would have taken 161 million shares.
KW is well aware that in its current state there is no market for 21.5 billion shares of BIEL.
She has to make BIEL profitable with a positive outlook and a much higher SP to have any chance of getting the IBEX loans paid back.
Since taking over as CEO in 2019 I have felt that she would take repayment in cash from future profits rather than conversion. Dr Staelin set a good example for this by making all of his new loans Non-Convertible since he returned to the COB job.
Dr Staelin made $268,000 in new Non-Convertible loans to BIEL in Q4 2022.
I am looking for a company update early next week as one is long overdue .
Once again, Who are you going to Trust
An anonymous message board poster or the FDA?
The FDA has thousands of scientists, experts in their fields, who know exactly how to analyze Medical Devices and the data used to support an FDA Clearance.
Clinical evidence from the ActiPatch Musculoskeletal Clearance K192234:
A randomized, controlled trial on chronic cervical osteoarthritis
(neck pain): This was a randomized, active-treatment controlled
study to evaluate the safety and effectiveness of the ActiPatch
medical device to reduce the pain level of patients diagnosed with
cervical osteoarthritis. The active-treatment control was an NSAID
of the Cox-2inhibitor family. There were 200 intent-to-treat
patients, out of which 197 completed the four-week study. There
were 142 women (71%) and 58 (29%) men in the study, with an
average age of 45 years. The primary endpoint for efficacy was
reduction in pain (VAS score) while at rest and being active, over
four weeks, when compared to the beginning of the study. The
results indicate that ActiPatch significantly reduced pain
(measured by VAS pain) associated with COA in the device
treatment group, and that the treatment differences between
device-treatment and NSAID-treatment groups was significant
(p<0.05).
A randomized controlled trial on osteoarthritis of the knee: The
osteoarthritis of the knee study was a double-blinded, randomized,
placebo-controlled study to evaluate the safety and effectiveness of
the ActiPatch medical device to reduce the pain level of patients
diagnosed with knee osteoarthritis. The placebo treatment was a
device that was identical to ActiPatch but did not produce an electromagnetic
field when turned on. There were 66 intent-to-treat
patients, out of which 60 patients completed the four-week study.
There were 43 women (71.6%) and 17 (16.4%) men in the study,
with the following average demographics at baseline: 68 years of
age, BMI of 27.4 and disease duration of 12.1 years. The primary
effectiveness endpoints were improvements in pain level over the
four weeks as measured by the before and after VAS score and
WOMAC scores, and the primary safety endpoint was all
treatment-related adverse events during the study. The results
indicate that ActiPatch significantly reduced pain (measured by
VAS pain) associated with KOA in the device treatment group,
and that the treatment differences between active and placebo
treatment groups was significant (p<0.05).
A randomized controlled trial on plantar fasciitis (heel pain): This
was a randomized, double-blinded, placebo-controlled study to
evaluate the safety and effectiveness of the ActiPatch medical
device to reduce the pain level of patients diagnosed with plantar
fasciitis. The placebo treatment was a device that was identical to
ActiPatch but did not produce an electromagnetic field when
turned on. A total of 70 patients were recruited into the study, and
all 70 completed the study. There were 52 women (74.4%) and 18
(25.6%) men in the study, with the following average
demographics at baseline: 51.5 years of age, BMI of 31.8 and
disease duration of 1.1 years. The primary effectiveness endpoint
was the daily morning (AM) VAS score, and the primary safety
endpoint was all treatment-related adverse events during the 7-day
study. The results indicate that ActiPatch significantly reduced
pain (measured by VAS pain) associated with PF in the device
treatment group, and that the treatment differences between active
and placebo treatment groups was significant (p<0.05).
Repeat Thursday
Thanks for confirming that Synergy's Kito Tech Deal is moving forward with product shipping to Synergy in Dubai.
<<<<<<<< he is shipping his product to a Synergy "facility" in Dubai. >>>>>>>>>
KitoTech Medical Inc. Signs Agreement with Synergy Corporation for International Distribution of Their Medical and Consumer Products
https://www.prweb.com/releases/2023/03/prweb19198552.htm
Thanks for confirming my point
The Q3 Sales numbers are sourced from the Q3 Financials, anyone can look them up on the OTC Markets website.
The "One Study" claim has no sourcing so it could be legit or it could just be an Opinion. Those who want credibility on the internet generally provide sourcing or state up front that it is an Opinion.
LOL, "one study" and "sometimes" those are absolutes you can count on
"One" unnamed study "sometimes", how can anyone ignore that reliable data?
The CC Synergy document says in point #3,
"First order will occur after we successfully register our product in seven countries".
<<<< I hope Kelly didn't give the Synergy guy any money up front for "regulatory approval." >>>>
The Registration was BIEL's responsibility not Synergy's.
Since Synergy is now a component of the IMS Group probably best to talk to IMS,
977-01-4251545/ 4251318 .
LOL, Yes Massive Dumping of 999k shares, $400 Worth
When BIEL gets Good News the Share Volume goes into the Hundreds of Millions of Shares:
10/12/2015 .... 726 million shares
02/07/2017 .... 667 million shares
02/22/2017 .... 519 million shares
05/01/2018 .... 390 million shares
07/01/2019 .... 753 million shares
02/03/2020 .... 489 million shares
01/19/2021 .... 372 million shares
01/26/2021 .... 426 million shares
02/11/2021 .... 465 million shares
02/12/2021 .... 472 million shares
02/25/2021 .... 470 million shares
And the Dollar Value on these days is well north of a Million $$$$.
Anytime our Amazon Reporter misses an update one can assume the Wave is back in the Top 100
Currently at #73.
"#73 in Muscle Stimulators & Accessories"
Good Grief, nothing "Huge" has happened all day
Everyone waiting on Financials and BIEL Update.
Total Volume = 799k shares
Dollar Value = $320
LOL, "the company" must have been 'Sales Track'
The University of California at San Diego disagrees with you
UCSD, one the top US Research Universities spending ($1.133 billion) more than Duke, Harvard and Stanford, under the supervision of Dr. Brian Ilfeld an experienced researcher with 200 scientific papers written, is funding research on the use of RecoveryRx for use in Phantom Limb Pain.
I will take the opinion of UCSD over an anonymous message board poster any day of the week.
Adcock Ingram is not the sole answer to BIEL's International Distribution but it could be an important partner as they are not strictly selling in South Africa but do business in 13 additional markets in Africa.
The potential of Adcock Ingram can be seen in the first two pharmacies stocking ActiPatch:
Dis-Chem with 315 stores
Arrie Nel with 69 stores
"Adcock Ingram is a leading South African pharmaceutical manufacturer listed on the Johannesburg Stock Exchange."
"The Company manufactures, markets, and distributes a wide range of healthcare products and is a leading supplier to both the private and public sectors of the market. Through the recent acquisition of Plush the Company expanded into the Homecare market."
"Adcock Ingram covers over 14 markets on the continent with a broad product range of OTC, Prescription, Hospital and FMCG products."
"Adcock Ingram is ranked as the second largest manufacturer in the private pharmaceutical market and is the second largest supplier to the public sector. Of note is the major share of the critical care market held by the company, being the largest supplier of critical care products to the public sector and hospitals."
"The Consumer division competes mainly in the unregulated Fast Moving Consumer goods (FMCG) market. Products are also distributed and marketed in modern and traditional trade outlets. It continues to focus on the marketing, selling and distribution of healthcare, personal care and homecare brands."
https://www.adcock.co.za/Aboutus
https://actipatch.co.za/actipatch-contact-us/
Calling Total BS
<<<<<<<<<< Another day of heavy downside volume >>>>>>>>>>>
Buys = 2.5 million shares
Sells = 3.3 million shares
Neutral = 2.2 million shares @ .00045
Only ones Selling today were the MMs
Buys = 10.9 million shares
Sells = 1.5 million shares
Neutral = 1.1 million shares
Shorting = 10.9 million shares
date .... Symbol .. Short vol .. Total vol
20230405 | BIEL | 10942000 |13645757